Zarogoulidis Paul, Huang Haidong, Tsiouda Theodora, Sardeli Chrysa, Trakada Georgia, Veletza Lemonia, Kallianos Anastasios, Kosmidis Christoforos, Rapti Aggeliki, Papaemmanouil Liana, Hatzibougias Dimitrios, Drougas Dimitrios, Bai Chong, Hohenforst-Schmidt Wolfgang
Pulmonary-Oncology Department, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China.
Respir Med Case Rep. 2017 Oct 26;22:283-286. doi: 10.1016/j.rmcr.2017.10.006. eCollection 2017.
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified. We report a rare case of a patient with lung cancer adenocarcinoma who developed vitiligo throughout his body after nivolumab administration.
由于缺乏早期症状和诊断预防方法，非小细胞肺癌仍在晚期才被诊断出来。在过去十年中，已经引入或探索了几种靶向治疗方法。与非特异性细胞毒性药物相比，酪氨酸激酶抑制剂和免疫疗法目前被认为是最有效和安全的治疗方法。关于酪氨酸激酶抑制剂，其不良反应已得到充分研究；然而，另一方面，对于免疫疗法仍有几个问题需要澄清。我们报告了一例罕见的肺癌腺癌患者，在使用纳武单抗后全身出现白癜风。
